#1 Clinical Trials Search in Europe

Darunavir

Darunavir is an important antiretroviral medication used in the treatment of HIV infections. This article examines several clinical trials that have investigated the safety, efficacy, and optimal dosing of darunavir in combination with other HIV medications. These studies aim to improve treatment outcomes for patients living with HIV by evaluating different dosing regimens, assessing long-term safety, and optimizing therapy based on patient-specific factors.

Table of Contents

What is Darunavir?

Darunavir is a medication used in the treatment of HIV-1 infection. It belongs to a class of drugs called protease inhibitors (PIs), which are essential components of antiretroviral therapy for HIV[1]. Darunavir is also known by its brand names Prezista® and TMC114[2][3].

How Darunavir Works

Darunavir works by inhibiting the HIV protease enzyme, which is crucial for the virus to replicate. By blocking this enzyme, Darunavir prevents HIV from making new copies of itself, thus helping to control the spread of the virus in the body[1].

Conditions Treated by Darunavir

Darunavir is primarily used to treat:

  • HIV-1 Infection: This is the main condition for which Darunavir is prescribed. HIV-1 is the most common type of HIV that affects humans[1][4].
  • Immunosuppression-related Infectious Diseases: As HIV weakens the immune system, Darunavir indirectly helps in managing infections that occur due to a compromised immune system[4].

Dosage and Administration

Darunavir is typically administered orally, often in combination with other HIV medications. The dosage can vary depending on the patient’s specific needs and treatment history. Some common dosing regimens include:

  • 800 mg once daily with 100 mg of ritonavir[5]
  • 600 mg twice daily with 100 mg of ritonavir twice daily[5]
  • 400 mg twice daily with 100 mg of ritonavir twice daily[5]

It’s important to note that Darunavir is usually taken with food to enhance its absorption[3].

Combination Therapy with Darunavir

Darunavir is often used in combination with other antiretroviral drugs to create a more effective treatment regimen. Some common combinations include:

  • Darunavir/Cobicistat: Cobicistat is used to boost the levels of Darunavir in the body[2].
  • Darunavir/Ritonavir: Ritonavir is another protease inhibitor that boosts Darunavir levels[5].
  • Darunavir with Dolutegravir: This combination is being studied as a potential two-drug regimen for HIV treatment[4].

Efficacy and Safety of Darunavir

Clinical trials have shown that Darunavir is effective in reducing HIV viral load (the amount of virus in the blood) and increasing CD4 cell count (a type of white blood cell that fights infection). In one study, 98% of patients maintained viral suppression after 48 weeks of treatment with Darunavir/ritonavir plus Dolutegravir[4].

Darunavir has also demonstrated efficacy in patients who have previously been treated with other HIV medications and have developed resistance to multiple drugs[1].

Potential Side Effects

Like all medications, Darunavir can cause side effects. Common side effects may include:

  • Diarrhea
  • Nausea
  • Rash
  • Headache
  • Abdominal pain

More serious side effects, though rare, can include liver problems and severe skin reactions. It’s important to discuss any side effects with your healthcare provider[1][5].

Drug Interactions

Darunavir can interact with various medications, including other HIV drugs, certain antibiotics, and medications for other conditions. For example, it may interact with buprenorphine, a medication used to treat opioid dependence[6]. Always inform your healthcare provider about all medications you’re taking to avoid potential interactions.

Ongoing Research

Research on Darunavir is ongoing to further improve its efficacy and explore new treatment strategies. Some areas of current research include:

  • Evaluating Darunavir in combination with other antiretroviral drugs for simplified treatment regimens[4].
  • Studying the pharmacokinetics (how the body processes the drug) of Darunavir in different dosing regimens[5].
  • Investigating the bioequivalence of generic versions of Darunavir compared to the brand-name version[3].
Aspect Details
Study Types Bioequivalence, dose-response, long-term safety, pharmacokinetic modeling
Dosing Regimens Various, including 400mg-800mg once or twice daily, always with ritonavir
Patient Populations HIV-1 infected adults and children, including treatment-experienced patients
Primary Outcomes Safety, tolerability, viral load reduction, pharmacokinetic parameters
Secondary Outcomes CD4+ cell count changes, adverse events, long-term efficacy
Study Durations Ranging from 24 weeks to several years for long-term follow-up
Combination Therapies Darunavir typically combined with ritonavir and other antiretroviral drugs

FAQ

  • What is the purpose of darunavir in HIV treatment? Darunavir is an antiretroviral medication classified as a protease inhibitor. It is used to treat HIV-1 infections by preventing the virus from multiplying in the body. Darunavir is typically given in combination with other HIV medications to suppress the virus and help maintain the patient's immune system.
  • How is darunavir usually administered? Darunavir is usually administered orally, either as tablets or oral suspension. It is typically given in combination with a low dose of ritonavir, which acts as a pharmacokinetic enhancer. Dosing regimens can vary, with some patients taking it once daily and others twice daily, depending on factors like treatment history and body weight.
  • What are some common side effects of darunavir? While specific side effects were not detailed in the provided trial information, common side effects of darunavir can include nausea, diarrhea, headache, and rash. The clinical trials aimed to assess the long-term safety and tolerability of darunavir in combination with other antiretroviral therapies.
  • How do researchers determine the effectiveness of darunavir treatment? Researchers assess the effectiveness of darunavir treatment through several measures, including viral load reduction (the number of HIV copies in the blood), changes in CD4+ T cell count (which indicates immune system health), and the proportion of patients achieving undetectable viral loads (typically defined as <50 copies/mL).
  • Why are different dosing regimens studied for darunavir? Different dosing regimens are studied to find the optimal balance between efficacy and tolerability for diverse patient populations. Factors such as treatment history, body weight, and genetic variations can affect how individuals respond to the medication. By studying various dosing strategies, researchers aim to develop personalized treatment approaches that maximize benefits while minimizing side effects.

Ongoing Clinical Trials on Darunavir

  • Study on Reducing HIV-HBV Treatment with Darunavir, Ritonavir, and Lamivudine for Patients with Controlled Co-Infection

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on HIV Treatment Interruption in Children with Perinatal HIV Using Lamivudine and Drug Combination

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany The Netherlands Poland Spain

  • Study Comparing Integrase Inhibitor (Bictegravir) and Boosted Protease Inhibitor (Darunavir) Treatments for Patients with Advanced HIV Infection

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Ireland Italy Spain

Glossary

  • Bioequivalence: A state where two medications with the same active ingredient have essentially the same bioavailability (rate and extent of absorption) in the body. This is important when comparing generic versions of a drug to the original brand-name version.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. This helps determine appropriate dosing and timing of medication administration.
  • Viral Load: The amount of HIV genetic material (RNA) in a blood sample, reported as copies per milliliter. A lower viral load indicates better control of the virus.
  • CD4+ T Cell Count: A measure of the number of CD4 T lymphocytes in the blood, which are important immune cells targeted by HIV. A higher CD4 count indicates a stronger immune system.
  • Protease Inhibitor: A class of antiretroviral drugs that block the action of protease, an enzyme that HIV needs to replicate. Darunavir is a protease inhibitor.
  • Ritonavir: A medication often used in small doses with other HIV drugs like darunavir to boost their effectiveness by slowing their breakdown in the body.
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time, used to assess the extent of drug absorption and overall effectiveness of a dosing regimen.

References

  1. https://clinicaltrials.gov/study/NCT02499978
  2. https://clinicaltrials.gov/study/NCT01928407
  3. https://clinicaltrials.gov/study/NCT04268472
  4. https://clinicaltrials.gov/study/NCT03683524
  5. https://clinicaltrials.gov/study/NCT00071097
  6. https://clinicaltrials.gov/study/NCT00877591